DUBLIN–(BUSINESS WIRE)–The “Optical Sorter Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)” report has been added to ResearchAndMarkets.com’s offering. The optical sorter market is expected to register a CAGR of 10% over the for…
Author: Business Wire
Haymarket Medical Network Launches Optometry Advisor
NEW YORK–(BUSINESS WIRE)–Haymarket Medical Network today launched Optometry Advisor, a new digital resource that empowers primary eye care physicians with comprehensive clinical, refractive, and pharmaceutical information. OptometryAdvisor.com meets …
New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
DUBLIN–(BUSINESS WIRE)–New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
GenSight Biologics annonce l’octroi par la FDA de la désignation Fast Track pour GS030 comme traitement optogénétique de la rétinopathie pigmentaire
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, éligible PEA-PME), une société biopharmaceutique dédiée au développement et à la commercialisation des thérapies géniques innovantes pour le traitement de…
GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of interim Phase 2 data wit…
ABIONYX Pharma initie des échanges avec la société IRIS Pharma, l’un des leaders mondiaux de la recherche préclinique et clinique en ophtalmologie, en vue d’un éventuel rapprochement stratégique
TOULOUSE, France & LAKELAND, Mich.–(BUSINESS WIRE)–Regulatory News: ABIONYX Pharma (Paris:ABNX) (FR0012616852 – ABNX), société biotech de nouvelle génération dédiée à la découverte et au développement de thérapies innovantes, annonce aujourd’hui init…
ABIONYX Pharma Initiates Discussions With IRIS Pharma, a World Leader in Preclinical and Clinical Ophthalmology Research, With a View to a Possible Strategic Deal
TOULOUSE, France & LAKELAND, Mich.–(BUSINESS WIRE)–Regulatory News: ABIONYX Pharma (Paris:ABNX) (FR0012616852 – ABNX – PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies, announced …
Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today a…
RxCell Inc., A*STAR’s IMCB, NUS, and SERI Collaborate to Develop Cellular Therapeutics for Age-related Diseases
SAN FRANCISCO–(BUSINESS WIRE)–RxCell, a Bay Area-based biotechnology company focused on therapeutic applications of induced pluripotent stem cells (iPSC), together with the Agency for Science, Technology and Research (A*STAR)’s Institute of Molecular…
The Worldwide Automated Optical Inspection Industry is Expected to Reach $1.6+ Billion by 2026 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Automated Optical Inspection Market with COVID-19 Impact Analysis by Type (2D AOI, 3D AOI), Technology (Inline AOI, Offline AOI), Industry, Application (Fabrication Phase, Assembly Phase), Elements of AOI, and Regio…
BVI宣佈投資Beyeonics Vision並展開合作
麻薩諸塞州沃爾瑟姆–(BUSINESS WIRE)–(美國商業資訊)–專業多元化的全球性眼科器材公司BVI今天宣佈，對Elbit Systems Ltd.（NASDAQ: ESLT和TASE: ESLT，簡稱“Elbit Systems”）旗下的醫療科技子公司Beyeonics Vision進行投資。Beyeonics Vision利用整合式擴增實境、追蹤和影像處理/人工智慧平臺，為手術中外科醫生的決策過程提供改進的視覺化、最佳化的工作流程和即時支援。此次合作還促使Beyeonics™ One…
BVI宣布投资Beyeonics Vision并与之开展合作
马萨诸塞州沃尔瑟姆–(BUSINESS WIRE)–(美国商业资讯)–专业多元化眼科器械跨国公司BVI今天宣布对Elbit Systems Ltd.（NASDAQ: ESLT和TASE: ESLT，简称“Elbit Systems”）旗下医疗技术子公司Beyeonics Vision进行投资。Beyeonics Vision利用一体式增强现实、跟踪和图像处理/人工智能平台，为手术中的外科医生的决策过程提供改进的可视化、优化的工作流程和实时支持。此次合作还促成了Beyeonics™ One在美国…
Medical Lasers Global Markets Report 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Medical Lasers Global Market Report 2021: COVID-19 Growth and Change to 2030” report has been added to ResearchAndMarkets.com’s offering. The global medical lasers market is expected to grow from $4.993 billion in 2020 to …
Novanta Renames Newly Acquired Company Novanta IMS, Highlights Opportunities Ahead
BEDFORD, Mass.–(BUSINESS WIRE)–Novanta Renames Newly Acquired Company Novanta IMS, Highlights Opportunities Ahead
GEHA Announces 2022 Health and Dental Plan Options and New Plan Perk for Select Offerings
LEE’S SUMMIT, Mo.–(BUSINESS WIRE)–Today, GEHA (pronounced G.E.H.A.) announced its 2022 health and dental plan options available to eligible federal employees through the Federal Employees Health Benefits (FEHB) Program and the Federal Employees Denta…
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 European Society of Cataract and Refractive Surgeons Annual Meeting
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that …
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an overview on Aerie’s retina product candidates, at the O…
2021 Report on Proliferative Vitreoretinopathy (Ophthalmology) Drugs In Development – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Proliferative Vitreoretinopathy (PVR) (Ophthalmology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering. This report provides an overview of the Proliferative Vitreoretinopathy (Ophth…
Bausch + Lomb: Positive Outcomes for Premium LuxSmart™ Intraocular Lenses, Following One-Year Real-World Experience
MONTPELLIER, France–(BUSINESS WIRE)–Bausch + Lomb today announced positive outcomes following the one-year real-world evaluation of its premium LuxSmart™ lens, since its European launch.